BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16565509)

  • 1. Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice.
    Arendt LM; Rose-Hellekant TA; Sandgren EP; Schuler LA
    Am J Pathol; 2006 Apr; 168(4):1365-74. PubMed ID: 16565509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterizations of Nop16 in murine mammary tumors with varying levels of c-Myc.
    Kundel DW; Stromquist E; Greene AL; Zhdankin O; Regal RR; Rose-Hellekant TA
    Transgenic Res; 2012 Apr; 21(2):393-406. PubMed ID: 21863248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERBB Receptors and Their Ligands in the Developing Mammary Glands of Different Species: Fifteen Characters in Search of an Author.
    Morato A; Accornero P; Hovey RC
    J Mammary Gland Biol Neoplasia; 2023 May; 28(1):10. PubMed ID: 37219601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin: The Third Hormone in Breast Cancer.
    Schuler LA; O'Leary KA
    Front Endocrinol (Lausanne); 2022; 13():910978. PubMed ID: 35784527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Spontaneous Aggressive ERα+ Mammary Tumor Model Is Driven by Kras Activation.
    Campbell KM; O'Leary KA; Rugowski DE; Mulligan WA; Barnell EK; Skidmore ZL; Krysiak K; Griffith M; Schuler LA; Griffith OL
    Cell Rep; 2019 Aug; 28(6):1526-1537.e4. PubMed ID: 31390566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland.
    Volker SE; Hedrick SE; Feeney YB; Clevenger CV
    Cancer Res; 2018 Jul; 78(14):3877-3887. PubMed ID: 29959151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival.
    Farooqui M; Bohrer LR; Brady NJ; Chuntova P; Kemp SE; Wardwell CT; Nelson AC; Schwertfeger KL
    Mol Cancer; 2015 Jul; 14():138. PubMed ID: 26215578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse.
    O'Leary KA; Shea MP; Schuler LA
    Adv Exp Med Biol; 2015; 846():201-20. PubMed ID: 25472540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo.
    O'Leary KA; Jallow F; Rugowski DE; Sullivan R; Sinkevicius KW; Greene GL; Schuler LA
    Endocrinology; 2013 Dec; 154(12):4483-92. PubMed ID: 24064365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells.
    Barcus CE; Keely PJ; Eliceiri KW; Schuler LA
    J Biol Chem; 2013 May; 288(18):12722-32. PubMed ID: 23530035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autocrine prolactin: an emerging market for homegrown (prolactin) despite the imports.
    Muthuswamy SK
    Genes Dev; 2012 Oct; 26(20):2253-8. PubMed ID: 23070811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin promotes mammary pathogenesis independently from cyclin D1.
    Asher JM; O'Leary KA; Rugowski DE; Arendt LM; Schuler LA
    Am J Pathol; 2012 Jul; 181(1):294-302. PubMed ID: 22658484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse models of estrogen receptor-positive breast cancer.
    Mohibi S; Mirza S; Band H; Band V
    J Carcinog; 2011; 10():35. PubMed ID: 22279420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
    Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
    Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.
    Sakamoto K; Triplett AA; Schuler LA; Wagner KU
    Oncogene; 2010 Sep; 29(39):5359-69. PubMed ID: 20639901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells.
    Carver KC; Piazza TM; Schuler LA
    J Biol Chem; 2010 Mar; 285(11):8003-12. PubMed ID: 20080972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes.
    Arendt LM; Evans LC; Rugowski DE; Garcia-Barchino MJ; Rui H; Schuler LA
    J Endocrinol; 2009 Oct; 203(1):99-110. PubMed ID: 19635758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex prolactin crosstalk in breast cancer: new therapeutic implications.
    Carver KC; Arendt LM; Schuler LA
    Mol Cell Endocrinol; 2009 Aug; 307(1-2):1-7. PubMed ID: 19524120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression.
    Arendt LM; Grafwallner-Huseth TL; Schuler LA
    Am J Pathol; 2009 Mar; 174(3):1065-74. PubMed ID: 19179608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SRC family kinases accelerate prolactin receptor internalization, modulating trafficking and signaling in breast cancer cells.
    Piazza TM; Lu JC; Carver KC; Schuler LA
    Mol Endocrinol; 2009 Feb; 23(2):202-12. PubMed ID: 19056863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.